Implanet Reports Q3 2019 Revenue of €1.7 Million, Up 12%

Regulatory News:

IMPLANET (Euronext Growth: ALIMP, FR0010458729, eligible for PEA-PME equity savings plans; OTCQX: IMPZY), a medical technology company specializing in vertebral and knee-surgery implants, today announces its revenue for the third quarter and first nine months to September 30, 2019.

Ludovic Lastennet, CEO of Implanet, commented: “In line with our objectives, the third quarter continues the growth pattern from the first and second quarters of the year. A 12% increase in the third quarter enables us to report +7% growth at the end of September. Our strategy of direct sales and partnerships with global players such as KICo Knee and SeaSpine have begun to bear fruit. The trajectory has been set, and we remain focused on the smooth rollout of our global strategic activities with focus on markets in which the margins generated will enable us to improve our profitability.”

Revenue (in € thousands - IFRS*)	2019	2018	Δ
1st quarter revenue	1,904	1,867	+2%
2nd quarter revenue	1,915	1,765	+8%
Spine (JAZZ)	1,189	1,056	+ 13%
Knee	550	491	+12%
3rd quarter revenue	1,739	1,548	+12%
Spine (JAZZ)	3,573	3,254	+10%
Knee	1,984	1,926	+3%
Total 9-month revenue	5,557	5,179	+7%

*Unaudited data

In the third quarter of 2019, Implanet recorded revenue of €1.74 million, up 12% on the €1.55 million recorded in Q3 2018. JAZZ activity generated sales of €1.19 million over the quarter, up 13% versus €1.06 million in Q3 2018. Knee activity grew by +12% to €0.55 million in the third quarter of 2019, thanks to the first delivery to KICo Knee.